2214 - A Phase II Study of Fruquintinib Combined with Tislelizumab and Sequential Radiotherapy for Recurrent or Oligoprogressive Esophageal Squamous Cell Carcinoma

03:00pm - 04:00pm ET

Poster Hall - Exhibit Hall A

Presenter(s)

Wenbin Shen, MD - The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei